The SELECT trial followed patients for over three years and demonstrated cardiovascular safety, even showing a 20% reduction in major adverse cardiovascular events
Pregnancy and breast-feeding
Healthcare providers can provide a personalized treatment plan by adjusting the doses of both drugs for optimal outcomes with minimal side effects
Metabolic indicators that may correlate with reduced GLP-1 activity include: Persistent hyperglycemia despite dietary modifications, particularly elevated postprandial (after-meal) blood glucose levels Difficulty achieving satiety after meals, leading to continued hunger and frequent snacking Progressive weight gain that is resistant to conventional dietary interventions Diagnosis of prediabetes or type 2 diabetes , conditions associated with impaired incretin response Metabolic syndrome features , including central obesity, hypertension, and dyslipidemia It is important to emphasize that these signs are not diagnostic of GLP-1 imbalance specifically, as they can result from numerous metabolic, endocrine, or lifestyle factors
Frequently Asked Questions Can I store oral semaglutide in my bathroom medicine cabinet
